Introduction: Immune checkpoint inhibitors have made a paradigm shift in the treatment of
non-small cell lung cancer (NSCLC). However, clinical response varies widely and robust …

Importance Advanced stage non-small cell lung cancer (NSCLC) patients with no driver
mutations are typically treated with immune checkpoint inhibitor (ICI)-based therapy, either in the …

This multicenter cohort study assessed the impact of molecular profiling (MP) on advanced
pancreaticobiliary cancer (PBC). The study included 30 patients treated with MP-guided …

PURPOSE Current guidelines for the management of metastatic non–small cell lung cancer
(NSCLC) without driver mutations recommend checkpoint immunotherapy with PD-1/PD-L1 …

This paper explores the feasibility for an undergraduate leadership studies pro-gram to be
established at Florida Atlantic University (FAU). Insight was obtained through focus groups …

Background: Immune checkpoint inhibitors (ICIs) have significantly improved outcomes for
patients with metastatic non-small cell lung cancer (NSCLC). However, clinical management …

Introduction: Treatment modality selection for metastatic NSCLC patients (immunotherapy
alone vs. combination of immunotherapy with chemotherapy) relies mainly on determining the …

e21132 Background: To date, predicting response to immune checkpoint blockade (ICB)
therapy in non-small cell lung cancer (NSCLC) patients is based on assessing PD-L1 levels in …

Background To date, predicting response to immune checkpoint blockade (ICB) therapy in
non-small cell lung cancer (NSCLC) patients is based on tumor PD-L1 levels. However, …

… Ron Epelbaum,1,2 Einat Shacham-Shmueli,3,4 Baruch Klein,4,5,6 Abed Agbarya,1
Baruch Brenner,4,7 Ronen Brenner,4,8 Eliahu Gez,4,9 Talia Golan,3,4 Ayala Hubert,10,11 …